Aquinox Pharmaceuticals Inc. (AQXP) Stock Rating Reaffirmed by Needham & Company LLC
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report issued on Thursday.
Other equities research analysts also recently issued reports about the company. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a report on Wednesday, August 17th. Jefferies Group upped their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a report on Friday, August 5th. Zacks Investment Research raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 4th. Finally, Leerink Swann began coverage on Aquinox Pharmaceuticals in a research report on Tuesday, October 4th. They set an “outperform” rating and a $24.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $20.00.
Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 13.52 on Thursday. The company’s 50-day moving average price is $12.04 and its 200 day moving average price is $9.49. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $15.76. The firm’s market capitalization is $239.17 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Wednesday, November 9th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.12. Equities research analysts predict that Aquinox Pharmaceuticals will post ($2.13) earnings per share for the current year.
In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the company’s stock in a transaction that occurred on Tuesday, September 20th. The shares were purchased at an average cost of $12.25 per share, with a total value of $34,099,161.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of AQXP. BlackRock Inc. raised its position in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock valued at $446,000 after buying an additional 9,900 shares during the last quarter. BlackRock Group LTD raised its position in shares of Aquinox Pharmaceuticals by 23.4% in the first quarter. BlackRock Group LTD now owns 200,100 shares of the company’s stock valued at $1,765,000 after buying an additional 37,900 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock valued at $8,558,000 after buying an additional 952,272 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Aquinox Pharmaceuticals during the second quarter valued at $166,000. Finally, Royce & Associates LP raised its position in shares of Aquinox Pharmaceuticals by 89.9% in the second quarter. Royce & Associates LP now owns 182,622 shares of the company’s stock valued at $1,209,000 after buying an additional 86,455 shares during the last quarter. 67.13% of the stock is currently owned by institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.